Levanger Hospital   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Levanger Norway (1844)

Organization Overview

First Clinical Trial
2018
NCT03540420
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Levanger Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Clostridium Infections (Phase 3)

Communicable Diseases (Phase 3)

Infections (Phase 3)

Lung Neoplasms (Phase 2)

Multiple Myeloma (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 6